# Calderasib

Source: https://onco.cc/drugs/calderasib/  
OnCo record `calderasib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Calderasib is an experimental small-molecule drug from Merck Sharp & Dohme in phase 3 trials for non-small-cell lung cancer and colorectal cancer, aimed at KRAS.

## Summary

Calderasib (MK-1084) is a small-molecule drug developed by Merck Sharp & Dohme. Its target is KRAS (the sponsor names KRAS G12C). The sponsor states: MK-1084 is described as an investigational, oral, selective KRAS G12C inhibitor. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07554339 (A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)), NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumour Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)) and NCT07431827 (MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)), in non-small-cell lung cancer and colorectal cancer. The largest, NCT07190248, plans to enrol 675 participants with primary completion expected 2029-12-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: MK-1084
- Modality: small molecule
- Mechanism: MK-1084 is described as an investigational, oral, selective KRAS G12C inhibitor.

## Sources

- ClinicalTrials.gov: trials of Calderasib: https://clinicaltrials.gov/search?intr=MK-1084
- Sponsor pipeline page: https://www.merck.com/research/product-pipeline/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)](https://onco.cc/trials/nct07190248/), [A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)](https://onco.cc/trials/nct07209111/), [A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)](https://onco.cc/trials/nct06997497/), [A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)](https://onco.cc/trials/nct07286149/), [A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)](https://onco.cc/trials/nct07554339/), [A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)](https://onco.cc/trials/nct06345729/), [KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)](https://onco.cc/trials/nct07252739/), [MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)](https://onco.cc/trials/nct07431827/)

---
JSON: https://onco.cc/api/v1/entities/calderasib.json